微生态制剂联合门冬氨酸鸟氨酸治疗亚临床肝性脑病的效果分析

摘要/Abstract

摘要： 目的观察微生态制剂与门冬氨酸鸟氨酸联合用于治疗亚临床肝性脑病(SHE)的疗效及对肝功能、认知功能的影响。方法于2020年1月—2023年12月期间筛选86例安徽理工大学第一附属医院收治的SHE患者并随机分组:对照组(43例)接受门冬氨酸鸟氨酸治疗,观察组(43例)加用微生态制剂治疗。治疗前及治疗8周后,检测血氨、C反应蛋白(CRP)、降钙素原(PCT)、肝生化指标[天冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、γ-谷氨酰转移酶(γ-GT)、总胆红素(TBil)],并评价认知功能量表数字连接试验(NCT)-A、NCT-B与数字符号试验(DST)结果。结果相比于对照组治疗后水平,观察组的血氨[(66.69±18.19) vs.( 87.88±21.35) μmol/L]、CRP[(6.57±1.43) vs.( 9.56±1.71) mg/L]、PCT[(0.21±0.08) vs. (0.29±0.09 )ng/L]、AST[(49.14±9.75) vs. (55.21±11.06) U/L]、ALT[(35.81±5.79) vs. (48.35±7.21)U/L]、γ-GT[(60.89±9.71) vs. (73.25±11.61)U/L]、TBil[(45.61±7.32) vs. (50.37±8.42)U/L]水平降低更显著(P<0.05)。与对照组比较,观察组NCT-A(56.68±11.06 vs. 60.01±12.14)、NCT-B(67.76±12.83 vs. 71.85±14.69)、DST(105.42±21.68 vs. 126.48±23.41)评估结果的降幅更显著(P<0.05)。观察组4.65%转化为HE,低于对照组的HE转化率(16.28%, P<0.05)。结论微生态制剂联合门冬氨酸鸟氨酸治疗SHE能够降低血氨及炎症因子水平,保护肝功能及认知功能,降低HE转化风险。

关键词: 亚临床肝性脑病, 微生态制剂, 门冬氨酸鸟氨酸, 肝功能, 认知功能

Abstract: Objective To observe the therapeutic effect of microecological agents combined with ornithine aspartate in treatment of patients with subclinical hepatic encephalopathy (SHE) and its influence on liver function and cognitive function. Methods A total of 86 SHE patients were collected from January 2020 to December 2023, and were randomly divided into two groups. The control group (43 cases) received ornithine aspartate treatment, and the observation group (43 cases) received ornithine aspartate combined with microecological agents. Before treatment and 8 weeks after treatment, the blood ammonia, C-reactive protein (CRP), procalcitonin (PCT), and liver function indicators [aspartate aminotransferase (AST), alanine aminotransferase (ALT), γ- Glutamyltransferase (γ- GT) and total bilirubin (TBil)] were measured. The cognitive function was evaluated by the Number Connection Test (NCT-A), NCT-B, and Digital Sign Test (DST). Results Compared to control group after treatment, the blood ammonia (66.69±18.19 μmol/L vs. 87.88±21.35 μmol/L), CRP (6.57±1.43 mg/L vs. 9.56±1.71 mg/L), PCT ( 0.21±0.08 ng/L vs. 0.29±0.09 ng/L), AST(49.14±9.75 U/L vs. 55.21±11.06 U/L), ALT(35.81±5.79 U/L vs. 48.35±7.21 U/L), γ- GT (60.89±9.71 U/L vs. 73.25±11.61 U/L) and TBil (45.61±7.32 U/L vs. 50.37±8.42 U/L) both decreased in the observation group, with statistical significance (all P<0.05). Compared to control group after treatment, the levels of NCT-A (56.68±11.06 vs. 60.01±12.14), NCT-B (67.76±12.83 vs. 71.85±14.69), and DST (105.42±21.68 vs. 126.48±23.41) in the observation group were significantly higher (all P<0.05). There was 4.65% of patients converted to HE in the observation group, significantly lower than the HE conversion rate of 16.28% in control group (P<0.05). Conclusion The combination treatment of microecological agents and ornithine aspartate can reduce blood ammonia and inflammatory factor levels, protect liver and cognitive function in SHE patients, and may reduce the risk of HE conversion.

Key words: Subclinical hepatic encephalopathy, Microecological preparations, Aspartate ornithine, Liver function, Cognitive function

李燕, 陈倩, 周淑萍, 刘新矿, 徐斌. 微生态制剂联合门冬氨酸鸟氨酸治疗亚临床肝性脑病的效果分析[J]. 肝脏, 2024, 29(7): 821-824.

LI Yan, CHEN Qian, ZHOU Shu-ping, LIU Xin-kuang, XU Bin. Efficacy of microecological agents combined with ornithine aspartate in treatment of patients with subclinical hepatic encephalopathy and its influence on liver function and cognitive function[J]. Chinese Hepatolgy, 2024, 29(7): 821-824.

/ 推荐

参考文献

[1] 徐华栋, 张玉婷. 亚临床肝性脑病患者肠道菌群和炎症因子水平变化及黄连素的干预作用[J]. 中国医学创新,2023,20(27):141-145.
[2] 张纵, 王晓花. 肝性脑病诊断及治疗进展[J]. 山东大学学报:医学版,2018,56(2):1-8.
[3] 李洁, 赵江明, 王黎, 等. 轻微型肝性脑病发病机制的研究进展[J]. 山东医药,2019,59(35):103-105.
[4] 李变玲, 黄会芳, 王晓阳, 等. 肠道菌群与肝性脑病的关系及其治疗措施研究进展[J]. 解放军医学杂志,2021,46(9):860-864.
[5] 中华医学会肝病学分会. 肝硬化肝性脑病诊疗指南(2018年,北京)[J]. 中华胃肠内镜电子杂志,2018,5(3):97-113.
[6] 郝良成, 胡阳黔, 侯晓华. 年龄和受教育程度矫正的数字连接测试和数字符号测试在诊断轻肝性脑病中的应用[J]. 中华肝脏病杂志,2015.(7):533-537.
[7] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy [J]. Hepatol,2022,77:807-824.
[8] 张亮, 李浩, 汤善宏. 肝硬化血氨相关肝性脑病的诊治思考[J]. 临床肝胆病杂志,2023,39(12):2942-2945.
[9] Arjunan A, Sah DK, Jung TD, et al. Hepatic encephalopathy and melatonin[J]. Antioxidants (Basel),2022,11(5):837.
[10] 鲁冰洁, 赵亚红, 安泳潼, 等. 肠道微生物失衡在肝性脑病中的研究进展[J]. 肝脏,2019,24(4):464-466.
[11] 王海强, 郑淑丹, 石璠, 等. 胆汁酸-微生态轴在肝硬化进展中的调节作用[J]. 肝脏,2023, 28(9):1119-1123.
[12] Yukawa-Muto Y, Kamiya T, Fujii H, et al. Distinct responsiveness to rifaximin in patients with hepatic encephalopathy depends on functional gut microbial species[J]. Hepatol Commun,2022,6(8):2090-2104.
[13] 刘宁静, 于慧静, 曹晓春. 门冬氨酸鸟氨酸联合乳果糖对老年肝性脑病疗效和NSE的影响[J]. 中南医学科学杂志,2023,51(4):579-581.
[14] 李文婧, 田杨, 程虹, 等. 双歧杆菌四联活菌片药学特性评价[J]. 中国临床药理学杂志,2023,39(18):2718-2723.
[15] 滕采万, 赵渝琼, 谢雪梅. 益生菌治疗对慢性乙型肝炎肝硬化亚临床肝性脑病患者临床疗效及对血氨和肠道菌群的影响[J]. 实用医院临床杂志,2019,16(2):92-94.
[16] 柳萍飞, 包健. 亚临床肝性脑病患者肠道菌群和血清炎症因子水平变化及益生菌的干预作用[J]. 中国微生态学杂志,2020,32(2):180-182,186.
[17] 范英超, 程芳, 司海骄. 肠道菌群和血清炎性因子变化及益生菌对肝性脑病的预防作用[J]. 当代医学,2021,27(30): 41-43.
[18] 王磊. 益生菌治疗慢性乙型肝炎肝硬化亚临床肝性脑病患者的临床疗效及对血氨和肠道菌群的影响[J]. 检验医学与临床,2019,16(9):1211-1214.
[19] 余芳杰. 乳果糖联合双歧杆菌三联活菌胶囊在轻微性肝性脑病患者中的应用效果[J]. 中国微生态学杂志,2020,32(8):929-932.
[20] 郑能, 于力力, 曹志. 双歧杆菌四联活菌治疗对肝硬化患者肝功能,细胞因子及肠道菌群的影响[J]. 解放军医药杂志,2020,32(8):36-39.
[21] 史俪璐, 徐慧, 陈慧. 双歧杆菌三联活菌胶囊联合乳果糖对经颈静脉肝内门体分流术后肝性脑病的预防效果分析[J]. 中国医学前沿杂志:电子版,2021,13(5):79-83.